Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Coffee Microcaps Morning Meeting (October 2022)
17 slides from Atomo Diagnostics's conference presentation, Oct 28, 2022
Slide 1: Atomo Investor Webinar Presentation
ASX Announcement 28 October 2022 For personal use only Atomo Investor Webinar Presentation Monday 31st October from 10am AEST - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce its participation in the Coffee Microcaps Morning Meeting. Chief Executive Officer John Kelly and Chief F
Slide 2: Coffee Microcaps Webinar
Atomo Diagnostics Limited For personal use only COFFEE MICROCAPS WEBINAR ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL
Slide 3: For personal use only
For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on omissions from, any other written or oral communications transmitted or otherwise made information available as at the date of this presentation. The information in this available to the recipie
Slide 4: Annual Sales Revenue and Q1 FY23 highlights
For personal use only Annual Sales Revenue ($m) • Cash receipts: cash receipts from customers for Q1 FY23 of $1.4m, with $892k in receipts from HIV rapid test sales and a further $472k from COVID-19* rapid antigen test sales 14.0 12.0 • Revenue: revenue (unaudited) of $877k for Q1 FY23, comprising $
Slide 5: For personal use only
For personal use only A visionary company reimagining consumer focused solutions and delivering best in class usability in the growing point of care testing market Strong financial position, committed investors, an experienced board & management team and a motivated cohort of professionals in the bu
Slide 6: Product engineering and user-centred design
For personal use only Atomo brings a level of product engineering excellence, human factors experience, consumer-centric design thinking and product validation rigor previously unseen in the diagnostics industry Our overriding product marketing requirement for any Atomo program is that our products
Slide 7: Understanding sources of error in workflow
For personal use only To design a product that truly addresses user needs, it is critical to really understand what causes sources of error Atomo assesses all workflow tasks and identifies sources of error Atomo products are designed to optimise deployment in untrained cohorts Conducting an initial
Slide 8: For personal use only
For personal use only ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 7
Slide 9: Development of the Atomo Galileo Platform
For personal use only Development of the Atomo Galileo Platform ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL
Slide 10: Issues with standard rapid tests vs Atomo devices
For personal use only “the lancet would not be out of place in a “I would rather pay for this test in future Christmas cracker” (than use a free test) if it means it is this easy” Home allergy test – UK, Boots feedback page Atomo HIV Self Test user – UK, Feefo Issues with standard rapid test kits: A
Slide 11: User feedback
For personal use only “Super easy quick test, top All surveyed users found it easy to use and instructions and quickly said that they would recommend it to implemented” others. South Africa, Iyeza Health Self Test User ,Germany, Amazon “Super Easy, Quick to Use.” Self Test User, Germany, Amazon “Sim
Slide 12: Atomo platforms: blood and swab
For personal use only Atomo platforms offer improved performance and usability in a variety of point of care settings and across an increasing number of sample types BLOOD SWAB Supports a broad range of swabs and multiple test applications (Nasal, nasopharyngeal, throat, STI and other types of swabs
Slide 13: HIV and Pascal platform products
For personal use only Atomo has developed and successfully launched the world’s first integrated, blood-based RDT solutions for professional use and self-test HIV screening: • With regulatory approvals including CE Mark for Europe, Australian TGA, and prequalification by the World Health Organisatio
Slide 14: eHealth and reader platform solutions
For personal use only Quick data capture and upload to Video and animation of user steps Affordable, accurate and disposable cloud – multiple languages reader platform - LED based Image Recognition to interpret Image Recognition to interpret Integrated lancet, blood and results results (less user er
Slide 15: HIV and home testing opportunity
HIV For personal use only • Atomo has seen a significant increase in enquiries and interest in new product development alongside increased interest in point of care and home-based testing post pandemic • Atomo’s executive team have been in the US several times this calendar year to support commercia
Slide 16: Commercial scale-up priorities
For personal use only Switching focus and investment from expansion of installed manufacturing capacity (now complete) to commercial scale up and business development, including focusing on: • Continued scale up of our HIV business globally • Expansion of senior commercial resourcing and associated
Slide 17: Atomo Diagnostics Limited contacts
Atomo Diagnostics Limited For personal use only John Kelly Will Souter CEO CFO john.kelly@atomodiagnostics.com will.souter@atomodiagnostics.com +61 401 922 279 +61 402 035 716 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENT
Atomo Diagnostics — Coffee Microcaps Morning Meeting (October 2022) on 6ix